According to Nice, osimertinib can help stop cancer from returning after surgery by targeting cells that have specific ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

A breakthrough daily pill which doubles the survival time for certain lung cancer patients will now be routinely available on ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.